奥浦迈(688293) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥93,779,111.15, an increase of 29.80% compared to the same period last year[3] - The total profit for the period was ¥20,072,789.92, reflecting a significant increase of 118.52% year-over-year[3] - The net profit attributable to shareholders was ¥11,878,406.38, marking a substantial growth of 283.59% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥7,791,833.40, which is an increase of 2,174.87% year-over-year[3] - Total profit for the year-to-date increased by 75.66%, driven by higher revenue leading to improved gross profit[9] - Net profit attributable to shareholders for the year-to-date was up by 81.48%, primarily due to revenue growth[9] - The total profit for the first three quarters of 2025 is CNY 68,924,070.17, compared to CNY 39,238,029.92 in the same period of 2024, representing an increase of approximately 75.8%[33] - The net profit for the first three quarters of 2025 is CNY 49,056,755.23, up from CNY 26,635,103.70 in 2024, indicating an increase of about 84.0%[33] Revenue and Growth - For the first three quarters of 2025, the company achieved operating revenue of CNY 271.53 million, a year-on-year increase of 25.79%[20] - The main business revenue reached CNY 271.18 million, reflecting a growth of 25.83% compared to the same period last year[20] - The cell culture products business generated revenue of CNY 238.60 million, marking a significant increase of 32.56% year-on-year, solidifying its position as the core revenue driver[20] - The CDMO service business reported revenue of CNY 32.58 million, showing a slight decline of 8.25% year-on-year due to external environment and customer demand fluctuations[21] Expenses and Costs - Research and development expenses totaled ¥12,235,563.44, accounting for 13.05% of operating revenue, an increase of 1.13 percentage points[4] - Research and development expenses rose to ¥36,377,735.69 in the first three quarters of 2025, up from ¥23,993,014.16 in 2024, marking an increase of 51.6%[32] - Total operating costs for the first three quarters of 2025 were ¥216,359,655.21, up from ¥186,064,262.52 in 2024, reflecting a growth of 16.2%[32] Cash Flow - The cash flow from operating activities for the period was ¥38,943,843.04, a decrease of 7.88% compared to the same period last year[3] - Cash flow from operating activities increased by 70.62% year-to-date, resulting from improved sales revenue and collection of receivables[9] - The operating cash flow for the first three quarters of 2025 is CNY 100,287,763.01, compared to CNY 58,777,458.30 in 2024, reflecting a growth of approximately 70.6%[36] - The company reported a decrease in cash flow from financing activities, with a net cash flow of -CNY 51,709,069.75 in 2025 compared to -CNY 95,877,104.85 in 2024, indicating an improvement[37] Assets and Liabilities - The total assets at the end of the period were ¥2,272,126,966.73, a slight decrease of 0.62% from the end of the previous year[4] - The company's cash and cash equivalents decreased to ¥741,681,201.59 as of September 30, 2025, from ¥891,143,542.80 at the end of 2024, a decline of 16.8%[28] - Total liabilities decreased to ¥172,553,849.21 as of September 30, 2025, from ¥190,970,352.87 at the end of 2024, a reduction of 9.6%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,682[12] - The top shareholder, Xiao Zhihua, holds 24.92% of the shares, totaling 28,301,943 shares[12] Strategic Initiatives - The company is focusing on expanding its market presence and investing in new product development to drive future growth[32] - The company successfully passed the EU Qualified Person audit, confirming compliance with EU GMP requirements, which supports its expansion into international markets[25] - The company is in the process of a major asset restructuring, with responses to regulatory inquiries completed and awaiting further approvals[27] Stock and Incentives - The company’s stock incentive plan saw the registration of 271,400 shares, increasing the total share capital from 113,548,754 shares to 113,820,154 shares[16] - The company’s antibody series culture medium was selected as one of the 200 innovative product application demonstration cases in the Yangtze River Delta region, highlighting its technological innovation[24] Accounting Standards - The company has not adopted new accounting standards for the year 2025[38]